Statin use and the risk of breast cancer: A population-based case-control study

Expert Opinion on Drug Safety

Volumn 13, Issue 3, 2014, Pages 287-293

  Chan, Te Fu ^a,b   Wu, Chen Hsuan ^c   Lin, Chih Lung ^a,b   Yang, Chun Yuh ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Breast cancer; Case control study; Pharmacoepidemiology; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; TAIWAN;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; RISK; TAIWAN;

EID: 84896722085     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.885949     Document Type: Article

References (56)

1. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002;16:508-19
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
3. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60
5. Goldstein MR, Mascitelli L, Pezzetta F. Do statin prevent or promote cancer? Curr Oncol 2008;15:76-7
6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002;360:1623-30
7. Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9
8. Dimitroulakos J, Marhin WH, Tokunaga J, et al. Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002;4:337-46
9. Park HJ, Hong D, Iruela-Arispe L, et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50
10. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45
11. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93
12. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer lines: An in vitro study. Carcinogenesis 2001;22:1139-48
13. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003;111:47-8
14. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf 2010;9:603-21
15. Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000;160:2363-8
16. Coogan P, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7
17. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94
18. Eliassen AH, Colditz GA, Rosner B, et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71
19. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33
20. Boudreau DM, Yu O, Miglioretti DL, et al. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21
21. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
22. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer 2005;114:643-7
23. Friedman GD, Flick D, Udaltsova N, et al. Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36
24. Pocobelli G, Newcomb PA, Trentham-Dietz A, et al. Statin use and risk of breast cancer. Cancer 2008;112:27-33
25. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usagerecord linkage study. Int J Cancer 2010;126:279-84
26. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: A series of nested case-control studies. BMC Cancer 2011;11:409
27. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011;71:1763-71
28. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7
29. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: A prospective study. J Womens Health 2003;12:749-56
30. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: Prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-7
31. Beck P, Wysowski DK, Downey W, et al. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-5
32. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy- 3-methylglutaryl-coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004;100:2308-16
33. Eaton M, Eklof J, Beal J, et al. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res 2009;29:5143-8
34. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17
35. Browning DR, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 2006;120:833-43
36. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A meta-analysis. JAMA 2006;295:74-80
37. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32
38. Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12
39. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: A meta-analysis of observational studies. Breast Cancer Res Treat 2012;135:261-9
40. Chiang CW, Chen CY, Chiu HF, et al. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007;16:412-21
41. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55
42. Jadhav SB, Jain GK. Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006;58:3-18
43. Meier CR, Scheinger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
44. Rejnmark L, Plsen ML, Johnsen SP, et al. Hip fracture risk in statin users- a population-based Danish case-control study. Osteoporos Int 2004;15:452-8
45. Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16
46. WHO collaborating center for drugs statistics methodology. ATC index with DDDs 2003. WHO; Oslo: 2003
47. Blanco-Colio LM, Villa A, Ortego M, et al. 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26
48. Danesh FR, Sadeghi MM, Amro N, et al. 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-5
49. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19
50. Shibata MA, Avanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9
51. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999;96:7797-802
52. Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol 2006;24:2128-9
53. Sprague JR, Wood ME. Statins and breast cancer prevention: Time for randomized controlled trials. J Clin Oncol 2006;24:2129-30
54. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev 2005;14:1897-8
55. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. Can Med Assoc J 2007;176:649-54
56. Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51